GCP
TNXP icon

GSA Capital Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

GSA Capital Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3
Closed -$80K – 1862
2022
Q2 		$80K Hold
3
– – 0.01% 1251
2022
Q1 		$435K Hold
3
– – 0.06% 635
2021
Q4 		$637K Buy
3
+2
+200% +$636K 0.08% 448
2021
Q3 		$310K Hold
1
– – 0.03% 996
2021
Q2 		$751K Hold
1
– – 0.08% 374
2021
Q1 		$554K Sell
1
-1
-50% -$765K 0.09% 295
2020
Q4 		$770K Buy
+2
New +$820K 0.13% 213
2020
Q3 		– Hold
0
– – – 1168
2020
Q2 		– Hold
0
– – – 564

Other funds holding TNXP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GSA Capital Partners's TNXP Position: Q3 2022 in Review

GSA Capital Partners sold out of Tonix Pharmaceuticals (TNXP) in Q3 2022, closing a stake of 3 shares — an estimated $80K sold.

GSA Capital Partners first reported a position in TNXP in Q4 2020 and held it in 7 quarters. The position peaked at $770K in Q4 2020. 19 funds tracked by Wall St. Rank hold TNXP as of Q3 2022.

  • GSA Capital Partners reported no remaining Tonix Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • GSA Capital Partners sold 3 Tonix Pharmaceuticals shares in Q3 2022, an estimated $80K.
  • GSA Capital Partners first reported a position in Tonix Pharmaceuticals in Q4 2020 and held it in 7 quarters.
  • GSA Capital Partners's Tonix Pharmaceuticals position peaked at $770K in Q4 2020.
  • 19 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2022.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.